Investor Webinar
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
LONDON and PHILADELPHIA - May 12, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that Dr Christina Coughlin, Chief Executive Officer, and Michelle Morrow, Chief Scientific Officer, will be presenting at a webinar on 15 May 2025 at 6.00 pm (BST).
| The webinar is open to all existing and potential investors and will focus on the Company's recent data presentations on its proprietary pre | CISION® candidates FAP-Dox (AVA6000) and FAP-EXd (AVA6103) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA. |
The Company welcomes investor interaction so there will be a Q&A session after the presentation and questions can be submitted pre-event as part of the registration process. The webinar will be hosted by Turner Pope Investments.
Investors can register for the event by using the following link:
| Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre | CISION® platform. pre | CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre | CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. | |
| About the pre | CISION® Platform | |||
| The pre | CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre | CISION® platform harnesses this tumor specific protease to cleave pre | CISION® peptide drug conjugates and pre | CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.